New treatment developments applied to elderly patients with advanced prostate cancer

Cancer Treatment Reviews

Volumn 39, Issue 6, 2013, Pages 578-583

  Mukherji, Deborah ^a   Pezaro, Carmel J ^b   Shamseddine, Ali ^a   De Bono, Johann S ^b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Abiraterone; Alpharadin; Cabazitaxel; Castration resistant prostate cancer; CRPC; Denosumab; Elderly; Enzalutamide; Sipuleucel T

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; CABAZITAXEL; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; MITOXANTRONE; PLACEBO; PREDNISOLONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIUM CHLORIDE RA 223; SIPULEUCEL T; ZOLEDRONIC ACID;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ASTHENIA; BLOOD PRESSURE MONITORING; BONE DENSITY; BONE METASTASIS; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CHILL; CLINICAL TRIAL (TOPIC); DEHYDRATION; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ELDERLY CARE; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HEART DISEASE; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; KIDNEY FAILURE; METASTASIS; NEUTROPENIA; OSTEOCLAST; OVERALL SURVIVAL; PAIN; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SEIZURE; SEPSIS; SIDE EFFECT; SPINE FRACTURE; TREATMENT RESPONSE; URINARY TRACT INFECTION; VISUAL ANALOG SCALE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

EID: 84878937422     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.12.004     Document Type: Review

References (44)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
2. La Vecchia C., Bosetti C., Lucchini F., Bertuccio P., Negri E., Boyle P., et al. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 2010, 21(6):1323-1360.
3. Dall'era M.A., Albertsen P.C., Bangma C., Carroll P.R., Carter H.B., Cooperberg M.R., et al. Active surveillance for prostate cancer: A systematic review of the literature. Eur Urol 2012.
4. Scosyrev E., Messing E.M., Mohile S., Golijanin D., Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer 2012, 118(12):3062-3070.
5. Basch E., Oliver T.K., Vickers A., Thompson I., Kantoff P., Parnes H., et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol 2012.
6. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(5):411-422.
7. de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376(9747):1147-1154.
8. de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364(21):1995-2005.
9. Parker C. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA). In: European multidsiciplinary cancer congress 2011, Stockholm; 2011.
10. Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012.
11. Armstrong A.J., Haggman M., Stadler W.M., Gingrich J.R., AssikisVJ, Nordle O., et al. Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): safety and efficacy analysis including subgroups. J Clin Oncol 2011, 29(Suppl. 7). [abstract 126].
12. Pezaro C.J., Omlin A., Mukherji D., Bianchini D., Sandhu S.K., Mulick Cassidy A., et al. J Clin Oncol 2012, 30(Suppl.). [abstract e15136].
13. Bok R.A., Small E.J. The treatment of advanced prostate cancer with ketoconazole: safety issues. Drug Saf 1999, 20(5):451-458.
14. Potter G.A., Barrie S.E., Jarman M., Rowlands M.G. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995, 38(13):2463-2471.
15. Barrie S.E., Potter G.A., Goddard P.M., Haynes B.P., Dowsett M., Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994, 50(5-6):267-273.
16. Attard G., Reid A.H., Yap T.A., Raynaud F., Dowsett M., Settatree S., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008, 26(28):4563-4571.
17. Ryan C.J., Smith M.R., Fong L., Rosenberg J.E., Kantoff P., Raynaud F., et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010, 28(9):1481-1488.
18. Marbury T., Stonerock R., Tran N., Marbury T., Gonzalez M. A Phase 1 single dose open-label reduced/staged pharmacokinetic (PK) and safety study of abiraterone acetate (AA) in men with impaired renal function. Eur J Cancer 2011, 47(Suppl. 1):S502.
19. Ryan C.J., Shah S., Efstathiou E., Smith M.R., Taplin M.E., Bubley G.J., et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011, 17(14):4854-4861.
20. Danila D.C., Morris M.J., de Bono J.S., Ryan C.J., Denmeade S.R., Smith M.R., et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010, 28(9):1496-1501.
21. Reid A.H., Attard G., Danila D.C., Oommen N.B., Olmos D., Fong P.C., et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010, 28(9):1489-1495.
22. Scher H.I., Heller G., Molina A.S. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 2011, 29(Suppl.):LBA4517.
23. Sternberg C.N., Scher H., Molina A., North S., Mainwaring P., Hao Y., et al. Fatigue improvement/reduction with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel - results from the cou-aa-301 phase 3 study. Eur J Cancer 2011, 47(Suppl. 1):S488-S489.
24. Ryan C.J., Smith M.R., de Bono J.S., Molina A., Logothetis C.J., de Souza P., et al. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. N Engl J Med. 2012, Dec 10 [epub ahead of print].
25. Mita A.C., Denis L.J., Rowinsky E.K., Debono J.S., Goetz A.D., Ochoa L., et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009, 15(2):723-730.
26. Aventis S. Jevtana prescribing information; December 2011. http://www.provenge.com/pdf/prescribing-information.pdf.
27. Bahl A., Masson S., Malik S., Birtle A., Sundar S., Jones R.J., et al. Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279). J Clin Oncol 2012, 30(Suppl. 5):44. [abstract 44].
28. Heidenreich A., Scholz H.J., Rogenhofer S., Arsov C., Retz M., Muller S.C., et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol 2012.
29. Droz J.P., Balducci L., Bolla M., Emberton M., Fitzpatrick J.M., Joniau S., et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010, 106(4):462-469.
30. Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115(16):3670-3679.
31. Dendreon. Provenge prescribing information; December 2011. http://www.provenge.com/pdf/prescribing-information.pdf.
32. Longo D.L. New therapies for castration-resistant prostate cancer. N Engl J Med 2010, 363(5):479-481.
33. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324(5928):787-790.
34. Scher H.I., Beer T.M., Higano C.S., Anand A., Taplin M.E., Efstathiou E., et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375(9724):1437-1446.
35. De Bono J.S., Fizazi K., Saad F., Taplin M.E., Sternberg C.S., Miller K., et al. Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. J Clin Oncol 2012, 30(Suppl.). [abstract 4519].
36. Saad F., Lipton A., Cook R., Chen Y.M., Smith M., Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110(8):1860-1867.
37. Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352(2):154-164.
38. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94(19):1458-1468.
39. Fizazi K., Carducci M., Smith M., Damiao R., Brown J., Karsh L., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377(9768):813-822.
40. Smith M.R., Egerdie B., Hernandez Toriz N., Feldman R., Tammela T.L., Saad F., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361(8):745-755.
41. Saad F., Smith M.R., Shore N.D., Oudard S., Miller K., Tombal B., et al. Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics. J Clin Oncol 2012, 30(Suppl.). [abstract 4510].
42. Snedecor S.J., Carter J.A., Kaura S., Botteman M. Cost-effectiveness of zoledronic acid (ZOL) versus denosumab (Dmab) in prevention of skeletal-related events (SREs) in castration-resistant prostate cancer metastatic to the bone (mCRPC). J Clin Oncol 2011, 29(Suppl.). [abstract 4581].
43. Luthy I.A., Begin D.J., Labrie F. Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 1988, 31(5):845-852.
44. Sundar S., Dickinson P.D. Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate. BMJ Case Rep 2012, 2012.